CYPHERPUNK TECHNOLOGIES INC. current report, 16 September 2021

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on September 16, 2021. The registrant is a Delaware corporation with principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Global Market under the symbol LPTX. The company is classified as an emerging growth company.

Key Financial Metrics

This filing is a report of "Other Events" and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.

Material Changes

The material event reported is the presentation of updated positive data from the DisTinGuish Study evaluating the combination of the Company's lead candidate, DKN-01, plus Tislelizumab. This data was presented as a poster at the European Society for Medical Oncology (ESMO) Congress on September 16, 2021.

Guidance, Outlook, and Risks

  • Management Commentary: The Company issued a press release highlighting the positive nature of the updated clinical data presented at ESMO.
  • Exhibits: The full text of the press release (Exhibit 99.1) and the poster presentation (Exhibit 99.2) are filed with this report.
  • Disclaimer: Information on or connected to the Company's website referenced in the press release is expressly not incorporated by reference into this filing.
  • Risks/Contingencies: No specific risks or contingencies are detailed in the body of this 8-K; investors are directed to the exhibits for clinical data details.

Investor Verification Checklist

  • Verify the specific clinical endpoints and statistical significance of the "positive data" in the attached ESMO poster (Exhibit 99.2).
  • Review the full press release (Exhibit 99.1) for details on the DisTinGuish Study design and patient population.
  • Confirm the regulatory status of DKN-01 and the combination therapy with Tislelizumab.
  • Note that this filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial health.